Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Other Non Operating Income (2018 - 2025)

Serina Therapeutics' Other Non Operating Income history spans 8 years, with the latest figure at $35000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 16.67% year-over-year to $35000.0; the TTM value through Sep 2025 reached $193000.0, down 29.56%, while the annual FY2024 figure was $228000.0, 19.43% down from the prior year.
  • Other Non Operating Income for Q3 2025 was $35000.0 at Serina Therapeutics, down from $68000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $437000.0 in Q1 2021 and bottomed at $2000.0 in Q3 2022.
  • The 5-year median for Other Non Operating Income is $35000.0 (2025), against an average of $59052.6.
  • The largest annual shift saw Other Non Operating Income crashed 99.31% in 2022 before it surged 9250.0% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $3000.0 in 2021, then soared by 33.33% to $4000.0 in 2022, then surged by 2125.0% to $89000.0 in 2023, then crashed by 51.69% to $43000.0 in 2024, then fell by 18.6% to $35000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Other Non Operating Income are $35000.0 (Q3 2025), $68000.0 (Q2 2025), and $47000.0 (Q1 2025).